Literature DB >> 20368896

The aging male population and medical care for benign prostatic hyperplasia in Canada.

Nigel S B Rawson, Fred Saad.   

Abstract

BACKGROUND: The male Canadian population is aging and more men will be seeking medical care for benign prostatic hyperplasia (BPH). We examined the projected increase in older Canadian males between 2005 and 2018 to evaluate urologic health-care needs.
METHODS: We used Statistics Canada population projections to derive predictions of the male population aged 50 or more from 2005 to 2018 and results from the Olmsted County Study of Urinary Symptoms to estimate numbers of males aged >/=50 with moderate to severe lower urinary tract symptoms (msLUTS) in the same period. Data from the Canadian Institute for Health Information were used to estimate the number of urologists in 2018.
RESULTS: The number of Canadian men aged >/=50 is projected to rise between 2005 and 2018 by 39.5% and the number with msLUTS by 41.3%. However, the number of practicing urologists in Canada in 2018 is likely to be similar to the 584 practicing in 2007. An increase in the number of urologists proportional to the increase in men aged >/=50 with msLUTS would require 799 urologists in 2018.
INTERPRETATION: Little opportunity exists to expand the number of trainees in urology. Other alternatives must be sought to deal with increased numbers of older men with msLUTS. Initial management of BPH has moved towards being a responsibility of primary care physicians, but they appear to view BPH as a quality-of-life issue. It is crucial that urologists work closely with primary care physicians to ensure that the management of LUTS progression is optimized.

Entities:  

Year:  2010        PMID: 20368896      PMCID: PMC2845749          DOI: 10.5489/cuaj.09092

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  7 in total

1.  Physician labour supply in Canada: a cohort analysis.

Authors:  Thomas F Crossley; Jeremiah Hurley; Sung-Hee Jeon
Journal:  Health Econ       Date:  2009-04       Impact factor: 3.046

2.  The prevalence of prostatism: a population-based survey of urinary symptoms.

Authors:  C G Chute; L A Panser; C J Girman; J E Oesterling; H A Guess; S J Jacobsen; M M Lieber
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

3.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

Review 4.  Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ?

Authors:  Martin M Miner
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

5.  Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia.

Authors:  Tania Stafinski; Devidas Menon; Kevin Harris; Gary Gray Md; Gian Jhangri
Journal:  Can Urol Assoc J       Date:  2008-04       Impact factor: 1.862

6.  The value of appropriate assessment prior to specialist referral in men with prostatic symptoms.

Authors:  M R Quinlan; B J O'Daly; M F O'Brien; S Gardner; G Lennon; D W Mulvin; D M Quinlan
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

7.  Diagnosis and management of benign prostatic hyperplasia in primary care.

Authors:  Simon Tanguay; Murray Awde; Gerald Brock; Richard Casey; Joseph Kozak; Jay Lee; J Curtis Nickel; Fred Saad
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

  7 in total
  8 in total

1.  Do more BPH patients mean more urologists or just better management strategies?

Authors:  J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  EBM in Canadian urology.

Authors:  Laurence Klotz
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  The value of a core clinical rotation in urology for medical students.

Authors:  Premal Patel; Jasmir G Nayak; Thomas B McGregor
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

4.  Undergraduate exposure to urology: impact of the distributed model of medical education in British Columbia.

Authors:  Nathan A Hoag; Reza Hamidizadeh; Andrew E MacNeily
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

5.  Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.

Authors:  Afisi Ismaila; Anna Walker; Amyn Sayani; Bruno Laroche; J Curtis Nickel; John Posnett; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013-06-12       Impact factor: 1.862

6.  The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Authors:  Neerav Monga; Amyn Sayani; Daniel A Rubinger; Timothy H Wilson; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

Review 7.  Pelvic ultrasound evaluation for benign prostatic hyperplasia: prediction of obstruction.

Authors:  Daniel B Rukstalis
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

8.  Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.

Authors:  Sophie N Lee; Basu Chakrabarty; Brad Wittmer; Melissa Papargiris; Andrew Ryan; Mark Frydenberg; Nathan Lawrentschuk; Ralf Middendorff; Gail P Risbridger; Stuart J Ellem; Betty Exintaris
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.